Navigation Links
Statins associated with lower cancer recurrence following prostatectomy
Date:6/27/2010

DURHAM, N.C. Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs, according to researchers at Duke University Medical Center. Researchers also found that higher doses of the drugs were associated with lower risk of recurrence.

The findings are published in the journal CANCER.

"The findings add another layer of evidence suggesting that statins may have an important role in slowing the growth and progression of prostate cancer," says Stephen Freedland, M.D., a member of the Duke Prostate Center and the Urology Section at the Durham Veterans Affairs Medical Center, and the senior author of the study. "Previous studies have shown that statins have anti-cancer properties, but it's not entirely clear when it's best to use them or even how they work."

Researchers examined the records of 1319 men who underwent radical prostatectomy included in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. They found that 18 percent of the men 236 were taking statins at the time of surgery.

Researchers followed the patients after surgery to evaluate recurrence rates, measured by slight rises in the PSA levels after surgery, a development known as "biochemcical recurrence." Time to biochemical recurrence is viewed as an important clinical factor because it is correlated with the risk of disease progression and death.

The authors found that 304 men had a rising PSA, including 37 (16 percent) of the statin users and 267 (25 percent) of the non-users. Taking into account various clinical and pathological features that differed between the two groups, the data showed that overall, statin use reduced the risk of biochemical recurrence by 30 percent.

Among men taking statins equivalent to 20 mg of simvastatin a day, the risk of recurrence was reduced 43 percent and among the men taking the equivalent of more than 20 mg of simvastatin a day, the risk of recurrence was reduced 50 percent. Men who took a statin dose the equivalent of less than 20 mg of simvastatin daily saw no benefit.

There were significant differences between those who took the drugs and those who did not. Statin users tended to be white, older and heavier than non-users. They also had lower clinical stages at diagnosis, but higher Gleason scores, a measure of tumor aggressiveness.

"These findings are intriguing, but we do need to approach them with some caution," says Robert Hamilton, M.D., a urologist at the University of Toronto and the lead author of the study. "For example, we don't know the diet, exercise or smoking habits of these men. So it's not entirely clear if the lower risk we detected is related to the statins alone it could be due to other factors we were not able to measure. We do feel, however, that based on these findings and those from other studies, the time is ripe to perform a well-controlled randomized trial to test whether statins do indeed slow prostate cancer progression."


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. MSU team studies connection between statins, tendon ruptures
2. Too Many Stroke Patients Go Without Statins
3. Some statins have unintended effects and warrant closer monitoring, study finds
4. Statins decrease risk of clot-related diseases
5. Statins Wont Lower Colon Cancer Risk
6. Do Statins Lower Male Sex Drive?
7. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
8. Statins may slow progression of multiple sclerosis, new study finds
9. Alternative to Statins Shows Promise
10. Statins May Benefit Prostate Cancer Patients
11. Statins Show Promise Against Sickle Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Utah (PRWEB) , ... April 21, 2017 , ... ... wilderness therapy treatment for adolescents and young adults, has kicked off its 4th ... April 23rd. This year’s theme is “Attachment Informed Therapy for Mental Health ...
(Date:4/21/2017)... ... 21, 2017 , ... The Patient Advocacy Community of The Beryl Institute presented ... Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions to the ... award at The Beryl Institute’s annual Patient Experience Conference on March 20 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... ... Providing for loved ones before one’s passing is of paramount importance. However, ... “Now more than ever there are some questions that are far too critical to ... attorney Lisa Edgar Dickman, founder of the Law Offices of Lisa Edgar Dickman. ...
(Date:4/21/2017)... ... ... During April 21-23, Super-Sod will join the vendor market of the Sacred ... — from the avid gardener to the landscape admirer — during the three-day schedule. ... a grand venue, and we are certainly looking forward to participating in this year’s ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
Breaking Medicine Technology: